Strata Skin Sciences PE Ratio 2010-2024 | SSKN
Current and historical p/e ratio for Strata Skin Sciences (SSKN) from 2010 to 2024. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Strata Skin Sciences PE ratio as of January 07, 2025 is 0.00.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Strata Skin Sciences PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2025-01-07 | 3.04 | 0.00 | |
| 2024-09-30 | 2.75 | $-2.66 | 0.00 |
| 2024-06-30 | 3.07 | $-2.43 | 0.00 |
| 2024-03-31 | 3.78 | $-3.30 | 0.00 |
| 2023-12-31 | 5.50 | $-3.10 | 0.00 |
| 2023-09-30 | 5.95 | $-2.00 | 0.00 |
| 2023-06-30 | 9.50 | $-2.00 | 0.00 |
| 2023-03-31 | 10.59 | $-1.60 | 0.00 |
| 2022-12-31 | 7.90 | $-1.50 | 0.00 |
| 2022-09-30 | 8.71 | $-1.70 | 0.00 |
| 2022-06-30 | 9.61 | $-1.60 | 0.00 |
| 2022-03-31 | 14.70 | $-0.80 | 0.00 |
| 2021-12-31 | 14.65 | $-0.80 | 0.00 |
| 2021-09-30 | 18.40 | $-0.70 | 0.00 |
| 2021-06-30 | 15.60 | $-0.90 | 0.00 |
| 2021-03-31 | 16.70 | $-1.70 | 0.00 |
| 2020-12-31 | 15.00 | $-1.30 | 0.00 |
| 2020-09-30 | 13.50 | $-1.40 | 0.00 |
| 2020-06-30 | 11.50 | $-1.30 | 0.00 |
| 2020-03-31 | 9.50 | $-0.80 | 0.00 |
| 2019-12-31 | 20.80 | $-0.50 | 0.00 |
| 2019-09-30 | 21.50 | $-0.30 | 0.00 |
| 2019-06-30 | 24.90 | $-0.10 | 0.00 |
| 2019-03-31 | 28.50 | $-0.70 | 0.00 |
| 2018-12-31 | 26.00 | $-2.00 | 0.00 |
| 2018-09-30 | 35.40 | $-3.00 | 0.00 |
| 2018-06-30 | 20.50 | $-58.10 | 0.00 |
| 2018-03-31 | 11.70 | $-62.70 | 0.00 |
| 2017-12-31 | 12.30 | $-71.70 | 0.00 |
| 2017-09-30 | 17.70 | $-75.20 | 0.00 |
| 2017-06-30 | 24.30 | $-27.00 | 0.00 |
| 2017-03-31 | 30.25 | $-33.30 | 0.00 |
| 2016-12-31 | 22.00 | $-36.00 | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.012B | $0.033B |
| Strata Skin Sciences, Inc. is a medical technology company which focused on the dermatology market. Its products include the XTRAC laser(R) and VTRAC(R) excimer lamp systems for treatment of psoriasis, vitiligo and other skin conditions as well as the MelaFind (R) system used for identification and management of melanoma skin cancer. Strata Skin Sciences, Inc., formerly known as MELA Sciences, Inc., is based in Horsham, Pennsylvania. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inspire Medical Systems (INSP) | United States | $5.669B | 176.81 |
| Hims & Hers Health (HIMS) | United States | $5.506B | 140.00 |
| Tempus AI (TEM) | United States | $5.393B | 0.00 |
| IRhythm Technologies (IRTC) | United States | $2.799B | 0.00 |
| Enovis (ENOV) | United States | $2.475B | 16.78 |
| Privia Health (PRVA) | United States | $2.357B | 196.40 |
| Azenta (AZTA) | United States | $2.286B | 122.05 |
| Omnicell (OMCL) | United States | $2.053B | 67.15 |
| 10x Genomics (TXG) | United States | $1.718B | 0.00 |
| Clover Health Investments (CLOV) | United States | $1.568B | 0.00 |
| Schrodinger (SDGR) | United States | $1.486B | 0.00 |
| Phreesia (PHR) | United States | $1.464B | 0.00 |
| Butterfly Network (BFLY) | United States | $0.846B | 0.00 |
| Standard BioTools (LAB) | United States | $0.651B | 0.00 |
| Fulgent Genetics (FLGT) | United States | $0.563B | 0.00 |
| Talkspace (TALK) | United States | $0.529B | 0.00 |
| Definitive Healthcare (DH) | United States | $0.476B | 82.40 |
| Health Catalyst (HCAT) | United States | $0.446B | 0.00 |
| TruBridge (TBRG) | United States | $0.297B | 86.52 |
| Pulmonx (LUNG) | United States | $0.257B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.209B | 0.00 |
| EUDA Health Holdings (EUDA) | Singapore | $0.114B | 0.00 |
| American Well (AMWL) | United States | $0.108B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.090B | 0.00 |
| HeartBeam (BEAT) | United States | $0.063B | 0.00 |
| CareCloud (CCLD) | United States | $0.062B | 0.00 |
| Outset Medical (OM) | United States | $0.061B | 0.00 |
| 111 (YI) | China | $0.054B | 0.00 |
| Zepp Health (ZEPP) | China | $0.043B | 0.00 |
| Zhongchao (ZCMD) | China | $0.043B | 0.00 |
| SHL Telemedicine (SHLT) | Israel | $0.041B | 0.00 |
| Movano (MOVE) | United States | $0.035B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.018B | 0.00 |
| MSP Recovery (MSPR) | United States | $0.016B | 0.00 |
| Streamline Health Solutions (STRM) | United States | $0.016B | 0.00 |
| ImmunoPrecise Antibodies (IPA) | Canada | $0.014B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.008B | 0.00 |
| Precipio (PRPO) | United States | $0.008B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.006B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.005B | 0.00 |
| Syra Health (SYRA) | United States | $0.004B | 0.00 |
| HeartSciences (HSCS) | United States | $0.004B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.003B | 0.00 |
| Future Health ESG (FHLT) | United States | $0.000B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.000B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.000B | 0.00 |